Table 2 Vaccine efficacy parameters and assumptions
Gender | Male | Female | ||||||
|---|---|---|---|---|---|---|---|---|
HPV genotype | 6 | 11 | 16 | 18 | 6 | 11 | 16 | 18 |
Against transient infection †,‡ | ||||||||
- Cervical, vaginal & vulvar diseases | ― | ― | 41.1 | 62.1 | ― | ― | 76.0 | 96.3 |
- Genital warts & HPV 6, 11 | 49.0 | 57.0 | ― | ― | 76.1 | 76.1 | ― | ― |
Against persistent infection | ||||||||
- Anal disease | ― | ― | 78.7 | 96.0 | ― | ― | 98.8 | 98.4 |
- Cervical, vaginal & vulvar diseases | ― | ― | ― | ― | ― | ― | 98.8 | 98.4 |
- Penile disease | ― | ― | 78.7 | 96.0 | ― | ― | ― | ― |
Against individual diseases | ||||||||
- Genital warts | 84.3 | 90.9 | ― | ― | 98.9 | 100.0 | ― | ― |